/
INMB
$1.62+$0.20 (+14.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$37.8M
27M shares
52-week range
$1.09 – $3.24
25% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
13.51%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-16.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $1.1M | $3.3M | $5.9M | $20.5M | $17.1M | $20.3M | $33.2M | $20.7M |
| Operating income | −$12.4M | −$7.8M | −$12.2M | −$29.2M | −$26.0M | −$29.7M | −$42.6M | −$30.9M |
| EBITDA | $0 | −$7.7M | $0 | −$1.2M | −$1.3M | −$267.0K | −$41.5M | −$45.8M |
| Net income | −$12.4M | −$7.7M | −$12.1M | −$30.3M | −$27.3M | −$30.0M | −$42.1M | −$45.9M |
| Net margin | — | — | -109990.9% | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| EPS (diluted) | -1.11 | -0.89 | -1.01 | -1.88 | -1.52 | -1.67 | -2.11 | -1.86 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $133333 | $-0.70 | $-0.70–$-0.70 | 2 |
| 2027 | $6M | $-0.76 | $-0.79–$-0.72 | 2 |
| 2028 | $25M | $-0.50 | $-0.67–$-0.33 | 2 |
| 2029 | $97M | $0.69 | $0.69–$0.69 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.76
Price
$1.62
Implied downside
-53%
Peer comparison
INmune Bio Inc. Common stock
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
www.inmunebio.com- Employees
- 21
- IPO / List date
- Feb 4, 2019
- HQ
- BOCA RATON, FL
Held by traders on TradeandTell
No one on the platform currently holds INMB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,000 | $19.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INMB yet.
